
    
      This Phase 3 study is a multi-center, open-label extension study in ambulant boys with DMD
      who have completed the 48-week treatment period of either viltolarsen or placebo in Study
      NS-065/NCNP-01-301. Patients will receive viltolarsen administered IV at weekly doses of 80
      mg/kg.

      Study NS-065/NCNP-01-302 will be comprised of a 96-week treatment period.
    
  